Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYXNASDAQ:CLPTNASDAQ:PDEXNASDAQ:TTOO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$2.15-4.0%$1.58$0.76▼$2.30$84.66M1.3181,162 shs29,608 shsCLPTClearPoint Neuro$11.29+0.3%$12.71$5.24▼$19.22$315.16M0.92253,748 shs373,360 shsPDEXPro-Dex$45.05+3.3%$45.59$16.84▼$70.26$142.15M0.1935,726 shs43,011 shsTTOOT2 Biosystems$0.14-0.7%$0.15$0.06▼$6.00$2.89M0.48579,420 shs45,890 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical-4.02%+13.16%+32.72%+85.34%+60.45%CLPTClearPoint Neuro+0.27%-4.00%-4.24%-7.00%+113.02%PDEXPro-Dex+3.35%+6.85%+14.81%-11.06%+151.25%TTOOT2 Biosystems-0.72%-1.43%-14.60%+15.06%-97.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical2.2714 of 5 stars0.05.00.04.21.61.70.6CLPTClearPoint Neuro2.3158 of 5 stars3.52.00.00.02.70.80.6PDEXPro-Dex2.2436 of 5 stars2.52.00.00.02.21.71.9TTOOT2 Biosystems2.3801 of 5 stars3.05.00.00.00.00.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ACLPTClearPoint Neuro 3.00Buy$25.00121.43% UpsidePDEXPro-Dex 3.00Buy$56.0024.31% UpsideTTOOT2 Biosystems 2.00Hold$5.003,536.36% UpsideCurrent Analyst Ratings BreakdownLatest CLPT, PDEX, TTOO, and APYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.69N/AN/A$0.38 per share5.66CLPTClearPoint Neuro$31.39M10.07N/AN/A$0.92 per share12.27PDEXPro-Dex$53.84M2.73$0.99 per share45.52$9.03 per share4.99TTOOT2 Biosystems$7.68M0.38N/AN/A($6.91) per share-0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.55N/AN/AN/A-42.37%-156.85%-31.92%8/6/2025 (Estimated)CLPTClearPoint Neuro-$18.91M-$0.76N/AN/AN/A-64.51%-78.09%-51.33%8/6/2025 (Estimated)PDEXPro-Dex$2.13M$2.8016.0921.87N/A14.61%29.08%16.19%9/4/2025 (Estimated)TTOOT2 Biosystems-$50.08MN/A0.00∞N/A-563.16%N/A-174.06%7/28/2025 (Estimated)Latest CLPT, PDEX, TTOO, and APYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CLPTClearPoint Neuro-$0.15-$0.22-$0.07-$0.22$8.21 million$8.49 million5/8/2025Q1 2025APYXApyx Medical-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 million5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ACLPTClearPoint NeuroN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ATTOOT2 BiosystemsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical3.215.454.64CLPTClearPoint NeuroN/A3.532.57PDEXPro-Dex0.282.731.45TTOOT2 BiosystemsN/A0.400.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%CLPTClearPoint Neuro30.08%PDEXPro-Dex15.28%TTOOT2 Biosystems23.18%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical16.80%CLPTClearPoint Neuro6.97%PDEXPro-Dex47.50%TTOOT2 Biosystems0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.79 million31.45 millionOptionableCLPTClearPoint Neuro11027.99 million26.04 millionOptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionableTTOOT2 Biosystems18021.04 million21.04 millionOptionableCLPT, PDEX, TTOO, and APYX HeadlinesRecent News About These CompaniesTTOO T2 Biosystems, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comT2 Biosystems Inc. (TTOO) After Hours QuoteJune 10, 2025 | nasdaq.comDespite Promising Technology, Did Operational Cost Structure Take Down T2 Biosystems?March 5, 2025 | 360dx.com3T2 Biosystems initiates major layoffs, seeks asset saleFebruary 22, 2025 | uk.investing.comMedical diagnostics firm T2 Biosystems cuts ‘substantially all’ workersFebruary 18, 2025 | bizjournals.comT2 Biosystems to be delisted from NasdaqFebruary 11, 2025 | msn.comT2 Biosystems stock plunges to 52-week low of $0.22January 30, 2025 | msn.comT2 Biosystems Inc’s Stock Drama: Could This Be a Game-Changer for TTOO Investors?January 24, 2025 | bovnews.comBT2 Biosystems stock plunges to 52-week low of $0.25January 21, 2025 | msn.comT2 Biosystems amends loan terms, extends maturity dateJanuary 18, 2025 | msn.comT2 Biosystems reports preliminary Q4 revenue $2.3MJanuary 7, 2025 | markets.businessinsider.comT2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024January 7, 2025 | markets.businessinsider.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial ResultsJanuary 7, 2025 | finance.yahoo.comT2 Biosystems Enhances Governance and Leadership StabilityJanuary 3, 2025 | tipranks.comT2 Biosystems announces sale of four T2Dx Intruments to European distributorDecember 18, 2024 | markets.businessinsider.comT2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European DistributorDecember 18, 2024 | finance.yahoo.comT2 Biosystems achieves milestone with 250,000th novel sepsis test shippedDecember 17, 2024 | markets.businessinsider.comT2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped GloballyDecember 17, 2024 | markets.businessinsider.comT2 Biosystems extends multi-year supplier agreement with VizientDecember 16, 2024 | markets.businessinsider.comT2 Biosystems Extends Supplier Agreement with Vizient Through March 2026 for Rapid Sepsis Detection ProductsDecember 16, 2024 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLPT, PDEX, TTOO, and APYX Company DescriptionsApyx Medical NASDAQ:APYX$2.15 -0.09 (-4.02%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$2.13 -0.02 (-0.70%) As of 08:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.ClearPoint Neuro NASDAQ:CLPT$11.29 +0.03 (+0.27%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$11.40 +0.12 (+1.02%) As of 09:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Pro-Dex NASDAQ:PDEX$45.05 +1.46 (+3.35%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$45.10 +0.05 (+0.11%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.T2 Biosystems NASDAQ:TTOO$0.14 0.00 (-0.72%) As of 07/2/2025 03:56 PM EasternT2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
